Verve Therapeutics’ (VERV) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Verve Therapeutics (NASDAQ:VERV) in a research report released on Tuesday,Benzinga reports.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Verve Therapeutics in a report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Royal Bank of Canada cut their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.50.

Verve Therapeutics Stock Performance

NASDAQ VERV opened at $5.84 on Tuesday. Verve Therapeutics has a 52 week low of $4.31 and a 52 week high of $13.63. The stock’s 50 day moving average price is $6.98 and its two-hundred day moving average price is $6.09. The stock has a market capitalization of $518.57 million, a price-to-earnings ratio of -2.37 and a beta of 1.77.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.14. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, equities research analysts forecast that Verve Therapeutics will post -2.49 EPS for the current year.

Institutional Trading of Verve Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VERV. Intech Investment Management LLC bought a new position in shares of Verve Therapeutics during the 3rd quarter worth approximately $165,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Verve Therapeutics by 28.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after purchasing an additional 126,110 shares during the last quarter. Algert Global LLC raised its position in shares of Verve Therapeutics by 63.1% in the third quarter. Algert Global LLC now owns 224,216 shares of the company’s stock valued at $1,085,000 after purchasing an additional 86,720 shares during the period. FMR LLC lifted its stake in shares of Verve Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after buying an additional 3,873 shares during the last quarter. Finally, Acuta Capital Partners LLC acquired a new stake in shares of Verve Therapeutics during the 3rd quarter worth about $707,000. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.